Driving primary care to deliver the best in cardiovascular health

The PCCS, alongside a number of other societies and associations across the UK, has come together to provide guidance on the safe switching of warfarin to DOACs.

This needs to be undertaken in a phased manner over the 12-week cycle of INR monitoring to protect the supply chain for ALL patients. As highlighted, many patients are not suitable for a switch from warfarin to DOACs and further guidance will be available shortly to support services providing care for these patients.

Further information here.

Coming soon: COVID-19 and CV Management Series – online learning bites


MEMBERSHIP

Membership is free for:
GPs
GPwSIs
GP Registrars
Nurses
Pharmacists
Physicians Associate


PCCS OBJECTIVES

  • Represent primary care cardiovascular health needs at policy level
  • Promote best practice in primary care cardiovascular health through education, training and service development
  • Support the development of primary healthcare professionals in cardiovascular medicine
  • Facilitate and lead primary care cardiovascular research
  • Influence commissioners for the next decade

News & Articles

Treatment of patients with ACEi or ARB in relation to COVID-19

The British Cardiovascular Society (BCS) together with the British Society for Heart Failure (BSH) have released the following joint statement with regards to the treatment of patients with ACEi or ARB in relation to COVID-19 as a response to press and social media coverage raising 'the possibility that treatment with ACEi or ARB could predispose individuals to adverse outcomes should they become infected with COVID-19,

'there is no evidence to support this assertion and that both organisations share the view of the European Society of Hypertension and the Renal Association that patients should continue treatment with ACEi and ARB unless specifically advised to stop by their medical team.'

Both Societies recommend that patients taking these drugs and presenting unwell with suspected or known COVID-19 infection should be assessed on an individual basis and their medication managed according to established guidance as found.

The Primary Care Cardiovascular Society fully supports the views expressed in the Joint British societies statement and those of the European Society of Hypertension and the Renal Association.

British Cardiovascular Society - Treatment of patients with ACEi or ARB in relation to COVID-19

https://mailchi.mp/bcs/bcs-newswire-795910

Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers

The Renal Association, UK position statement on COVID-19 and ACE Inhibitor/Angiotensin Receptor Blocker use

In line with these statements, PCCS have developed some specific advice for patients which can be found here COVID_19_and_cardiac_treatment.pdf

Announcing the all new, highly interactive conference for primary care
Announcing the all new, highly interactive conference for primary care

Issues & Answers in Primary Care Today – CVplus: Because CVD is never alone 20-21 November 2020, Jurys Inn Hinckley Island Hotel & Conference Venue

British Heart Valve Society (BHVS) - Clinic Study Day
British Heart Valve Society (BHVS) - Clinic Study Day

BHVS Valve Clinic Study Day - 23rd June 2020 
Crowne Plaza, Birmingham 

BSH Heart Failure Nurse and Healthcare Professionals Education Day - Friday 27th March 2020
BSH Heart Failure Nurse and Healthcare Professionals Education Day - Friday 27th March 2020

British Society for Heart Failure's 10th Annual Heart Failure Nurse and Healthcare Professionals Education Day 

EPCCS - Annual Cardiovascular Summit for Primary Care - 2020
EPCCS - Annual Cardiovascular Summit for Primary Care - 2020

Professor Ahmet Fuat will be presenting at the European Primary Care Cardiovascular Society - Annual Cardiovascular Summit for Primary Care on March 19th - 20th - Prague, Czech Republic 

https://ipccs.org/2019/07/23/epccs-summit-2020/

Professor Ahmet Fuat - Primary Care Heart Failure
Professor Ahmet Fuat - Primary Care Heart Failure
Updated NICE Heart Failure guidelines - furthering evidence or a missed opportunity

Please come and see us at this year's PCCJ conference - Issues & Answers in Cardiovascular Disease, 16th-17th November 2018, East Midlands Conference Centre, Nottingham.

Our stand will be in the main hall, plus our session this year is: Updated NICE Heart Failure guidelines - furthering evidence or a missed opportunity 17.30-18.40, Conference Suite 1. This will be immediately followed by our AGM from 18.40 - 19.15. We look forward to seeing you there.

2nd PCCS Annual Conference – Guidelines into Practice
2nd PCCS Annual Conference – Guidelines into Practice
Professor Ahmet Fuat becomes a Fellow of the Royal College of Physicians of Edinburgh
Professor Ahmet Fuat becomes a Fellow of the Royal College of Physicians of Edinburgh

Congratulations to Professor Ahmet Fuat, President of the PCCS, for being elected as a Fellow of the Royal College of Physicians of Edinburgh. Professor Fuat said “he is honoured and humbled” Professor Fuat has been in general practice in Darlington since 1986, having graduated from Aberdeen University. He is a Fellow of the RCGP and RCP London.

As well as being a North East and North Cumbria GP Research Engagement Lead and CCG Cardiology Lead, he also works as a GP specialist in Cardiology and for 16 years has run an integrated heart failure service across primary and secondary care in Darlington. Holding a PhD from Durham University he is an active researcher in cardiology and was holds an honorary chair in Primary Care Cardiology from Durham University School of Health, Medicine and Pharmacy. Professor Fuat sits on the editorial boards of both the BJC and PCCJ and is an active member of the BCS and the BSH. He has published widely in peer reviewed journals. He is a tutor on the Bradford postgraduate diploma in cardiology course and chairs and lectures in cardiology nationally and internationally. He has served on the NICE and ESC guideline development groups on heart failure (acute and chronic) and myocardial infarction respectively.

Dr Derek Connolly describes the results of the COMPASS trial
Dr Derek Connolly describes the results of the COMPASS trial
Committee Announcement 20th June 2019
Committee Announcement 20th June 2019
The CREDENCE study – adding yet more to the existing cardiovascular outcomes studies with SGLT2 inhibition
The CREDENCE study – adding yet more to the existing cardiovascular outcomes studies with SGLT2 inhibition

Bev Bostock RGN MSc MA Queen’s Nurse Nurse Practitioner Mann Cottage Surgery Gloucestershire PCCS nurse board member Renal impairment, including end stage renal disease is a major concern in the management of diabetes and has a significant impact on patients, their families and resources1,2. It is estimated that the need for dialysis (which is very costly, has a negative impact on quality of life and has a poor prognosis) is set to rise from 3 million to 5 million people worldwide by 2035, especially with the increasing prevalence of diabetes3.

Become a
member

Annual
Conference

MEMBERSHIP

Membership is free for:
GPs
GPwSIs
GP Registrars
Nurses
Pharmacists
Physicians Associate